Review Draft Recommendations to Define Biomarker Testing for Diffuse Gliomas
Prazo estendido até 31/10/2019
International Academy of Pathology
With the advanced understanding of diffuse gliomas as discrete genetic and clinical entities, biomarker testing has become an established component of the integrated diagnosis of these tumors, allowing for a more refined definition of disease and better prediction of both prognosis and therapeutic response.
In order to develop an evidence-based guideline for the optimal diagnostic testing for pediatric and adult patients with diffuse gliomas, we rely on your expert knowledge.
The College of American Pathologists (CAP) in collaboration with the American Society of Clinical Oncology, the Society for Neuro-Oncology, the American Association of Neuropathologists and the Association for Molecular Pathology encourage all stakeholders—including oncologists, pathologists, neurosurgeons, nurses, and allied professionals—to review and submit feedback on the draft recommendations. We also encourage you to share this information with your membership.
Thank you for your consideration.
Daniel J. Brat, MD, PhD, FCAP
Guideline Expert Panel Chair
Patrick L. Fitzgibbons, MD, FCAP
Center Guideline Committee, Chair
College of American Pathologists